Therachon

About:

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases

Twitter/X: therachon

Top Investors: Bpifrance, New Enterprise Associates, OrbiMed, Versant Ventures, Novo Holdings

Description:

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Total Funding Amount:

$100M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Basel, Basel-Stadt, Switzerland

Founded Date:

2014-01-01

Contact Email:

nathalie.lenzin(AT)therachon.com

Founders:

Elvire Gouze, Luca Santarelli

Number of Employees:

1-10

Last Funding Date:

2018-08-09

IPO Status:

Private

Industries: